Novo Nordisk (NOVOB.DK) shares are gaining 3.0% after the company raised its sales forecast for 2023 on strong demand for Ozempic and Wegovy medicines.
- Operating profit at constant exchange rates +40% to +46%, previously expected +31% to +37%, Bloomberg estimated +37.5%
- Sales at constant exchange rates +32% to +38%, previously expected +27% to +33%, Bloomberg estimated +31.7%.
Meta Announces Its Own AI Chips. Is the Era of Full Dependence on NVIDIA Slowly Coming to an End?
Vodafone shares surge 13% after Xavier Niel's £4.4 billion investment. What's next for the stock?
🚩 Apollo Global warns on AI: Has the market become too optimistic?
Stock of the Week: Seagate Technology. How an old technology found a new role in the era of artificial intelligence